{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056451","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.732209+00:00","generated_at":"2026-06-28T09:18:33.004299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PMV Pharma Q3 2021 net loss $39.5M for nine months; cash $326.3M","bullets":["Net loss for nine months ended Sep 30, 2021: $39.5M vs $24.0M in prior-year period.","Cash, equivalents and marketable securities: $326.3M as of Sep 30, 2021; sufficient through end of 2023.","R&D expenses increased to $24.3M (from $17.8M) driven by PC14586 clinical development.","Phase 1/2 trial of p53 Y220C reactivator PC14586 data expected in first half 2022.","Appointed Tim Smith as SVP, Head of Corporate Development."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056451","json":"https://secwatch.observer/filing/0001564590-21-056451.json","markdown":"https://secwatch.observer/filing/0001564590-21-056451.md","text":"https://secwatch.observer/filing/0001564590-21-056451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000156459021056451/0001564590-21-056451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000156459021056451/pmvp-8k_20211112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:18:33.004299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}